Compras y ventas de directivos de DexCom (DXCM)
Qué compran y venden los consejeros y directivos del S&P 500 en sus propias empresas, tal cual lo presentan en los Formularios 4 de la SEC (2 días hábiles de plazo): cada fila con su código oficial y sin filtrar nada.
Las compras en mercado abierto (código P) son la señal rara, en verde; las ventas (código S) son frecuentes y muchas van programadas (10b5-1). La tabla II (derivados) no se incluye: sus precios son de ejercicio, no de mercado. Guía: compras de directivos.
| Fecha | Ticker | Directivo | Cargo | Acciones | Precio | Importe | % posición | Tipo / documento |
|---|
Descargar estas transacciones en CSV Sin cuenta y sin registro. Los datos son públicos: salen de los Formularios 4 de la SEC.
Compras y ventas de directivos de DexCom, Inc. (DXCM): 1 compra y 31 ventas
84 transacciones de la tabla I del Formulario 4 declaradas ante la SEC por directivos de DexCom, Inc. entre el 2025-09-04 y el 2026-10-19 (histórico de 15 meses): 1 compra y 31 ventas en mercado abierto, y 52 transacciones con otros códigos del Formulario 4, desglosados uno a uno más abajo. La mayor operación en mercado abierto es una venta de $2,4M de Sayer Kevin R el 2026-08-20.
Compras y ventas de directivos de DexCom en los últimos 12 meses
Entre el 21 oct 2025 y el 20 oct 2026, los directivos de DexCom declararon 1 compra por $1,0M y 28 ventas por $12,8M en mercado abierto. El saldo neto es vendedor: salen $11,8M más de los que entran.
Quien más compró fue Leach Jacob Steven (President & COO): $1,0M en 1 compra, el único comprador. Quien más vendió fue Sayer Kevin R (Executive Chair): $8,3M en 4 ventas, de 9 vendedores distintos.
La mayor operación del período fue una venta de $2,4M el 20 ago 2026, de Sayer Kevin R (Executive Chair), dentro de un plan 10b5-1. Formulario 4 en sec.gov (0001093557-26-000151).
Las 28 ventas llevan en el Formulario 4 la marca de plan 10b5-1: todas estaban programadas con meses de antelación.
En los tres últimos meses hay 0 compras y 12 ventas, frente a 0 y 10 en los tres anteriores. La última compra es del 10 nov 2025; la última venta, del 15 oct 2026.
Frente a su sector (Salud, 59 empresas con página de directivos en esta web), en las mismas fechas la mediana es de 9 ventas y 0 compras en mercado abierto. DexCom tiene más ventas que 50 de las otras 58, es la 35.ª de 59 por dinero neto vendido, y 19 de las 59 tienen al menos una compra, DexCom incluida.
Las 20 operaciones más importantes
Primero la única compra en mercado abierto y después el resto, cada tipo de mayor a menor importe. El histórico completo está en la herramienta de arriba, ya buscado.
Ver las 84 operaciones de DXCM en el histórico completo →
| Operación | Declarada | Directivo | Cargo | Importe | Código | Documento |
|---|---|---|---|---|---|---|
| 2025-11-10 | 2025-11-10 | Leach Jacob Steven | President & COO | $1,0M | P — Compra en mercado abierto3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 This transaction was executed in multiple trades at prices ranging from $54.34 to $55.33. The price above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 This transaction was executed in multiple trades at prices ranging from $55.34 to $55.55. The price above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 Included in this number are 84,537 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 8,465 of which were granted on March 8, 2023 and shall vest through March 8, 2026. | SEC |
| 2026-08-20 | 2026-08-24 | Sayer Kevin R | Executive Chair | $2,4M | S — Venta en mercado abierto (programada 10b5-1)4 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. F4 This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. | SEC |
| 2026-07-20 | 2026-07-21 | Sayer Kevin R | Executive Chair | $2,0M | S — Venta en mercado abierto (programada 10b5-1)3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 This transaction was executed in multiple trades at prices ranging from $75.80 to $76.62. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2026-05-21 | 2026-05-26 | Sayer Kevin R | Executive Chair | $1,9M | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2026-07-06 | 2026-07-07 | Sayer Kevin R | Executive Chair | $1,9M | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2026-09-15 | 2026-09-16 | Augustinos Nicholas | Consejero | $550k | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: by Trust 2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On June 10, 2026, Mr. Augustinos adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Augustinos. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Shares are held by the Kirschner/Augustinos Revocable Trust, with respect to which the Reporting Person is a trustee. | SEC |
| 2026-06-04 | 2026-06-05 | Coleman Jon | EVP, Chief Commercial Officer | $364k | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On March 4, 2026, Mr. Coleman adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Coleman. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 Included in this number are 95,450 unvested restricted stock units, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 51,553 of which were granted on May 22, 2025 and shall vest through May 22, 2029. | SEC |
| 2026-06-03 | 2026-06-05 | Coleman Jon | EVP, Chief Commercial Officer | $359k | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 On March 4, 2026, Mr. Coleman adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Coleman. The shares set forth above were sold pursuant to the 10b5- 1 Plan. | SEC |
| 2025-09-02 | 2025-09-04 | Sylvain Jereme M | EVP, Chief Financal Officer | $358k | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On May 27, 2025, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026. | SEC |
| 2026-09-10 | 2026-09-14 | Sylvain Jereme M | EVP, Chief Financal Officer | $303k | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On June 10, 2026, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 76 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. | SEC |
| 2026-06-15 | 2026-06-17 | Foletta Mark G | Consejero | $297k | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: by Trust 4 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 This transaction was executed in multiple trades at prices ranging from $73.70 to $74.685. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. F4 This transaction was executed in multiple trades at prices ranging from $74.78 to $75.55. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. | SEC |
| 2026-08-27 | 2026-08-28 | Stern Sadie | EVP Chief People & Culture Off | $227k | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On May 28, 2026, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2026-09-28 | 2026-09-30 | Stern Sadie | EVP Chief People & Culture Off | $221k | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On May 28, 2026, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2025-11-10 | 2025-11-10 | Collins Richard Alexander | Consejero | $218k | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: by Trust 2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On August 7, 2025, the Richard A. Collins Revocable Trust (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee. | SEC |
| 2025-11-14 | 2025-11-17 | Collins Richard Alexander | Consejero | $172k | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: by Trust 2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On August 7, 2025, the Richard A. Collins Revocable Trust (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee. | SEC |
| 2026-08-03 | 2026-08-04 | Foletta Mark G | Consejero | $171k | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: by Trust 2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. | SEC |
| 2026-07-31 | 2026-08-04 | Foletta Mark G | Consejero | $160k | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: by Trust 2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. | SEC |
| 2026-08-14 | 2026-08-17 | Brown Michael Jon | EVP Chief Legal Compliance Off | $156k | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2026-10-15 | 2026-10-19 | Brown Michael Jon | EVP Chief Legal Compliance Off | $145k | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. | SEC |
| 2026-09-15 | 2026-09-16 | Brown Michael Jon | EVP Chief Legal Compliance Off | $143k | S — Venta en mercado abierto (programada 10b5-1)2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 83 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan. | SEC |
El saldo del período: cuánto dinero entra y cuánto sale
En los Formularios 4 presentados entre el 4 sept 2025 y el 19 oct 2026, el mercado abierto de DexCom, Inc. suma 1 compra por $1,0M y 31 ventas por $13,3M. El saldo es de $12,3M a favor de las ventas.
Solo cuentan los códigos P y S, donde el directivo pone o saca su propio dinero. Que el saldo de DexCom, Inc. salga vendedor es lo habitual en el S&P 500, donde buena parte del sueldo se cobra en acciones. No es una recomendación de comprar ni de vender: es lo que se declaró.
Todas las transacciones, código por código
| Código | Qué significa | Operaciones | Importe declarado |
|---|---|---|---|
| S | Venta en mercado abierto | 31 | $13,3M |
| A | Adjudicación o premio de acciones | 24 | $0 |
| F | Retención fiscal (acciones entregadas por impuestos) | 19 | $12,4M |
| G | Regalo o donación | 9 | $0 |
| P | Compra en mercado abierto | 1 | $1,0M |
| Total | Todo lo declarado en el período | 84 | $26,7M |
33 de las 84 filas no traen un importe utilizable en el Formulario 4: cuentan como operación y suman $0. Las etiquetas son las del índice de códigos de la SEC.
Quién ha operado
En los 15 meses del histórico han declarado operaciones de DexCom, Inc. 17 personas o entidades distintas. De ellas, 1 compró en mercado abierto y 10 vendieron. Se cuentan por su CIK, el número fijo que la SEC da a cada declarante, y no por el nombre, que cada uno escribe a su manera.
De los 10 que vendieron en mercado abierto (31 ventas en total), los tres que más vendieron suman $10,0M de los $13,3M: el 76% del dinero en tres personas.
| Declarante | Cargo | Transacciones | Comprado (nº) | Vendido (nº) | Última declarada |
|---|---|---|---|---|---|
| Sayer Kevin R | Executive Chair | 8 | — | $8,3M (4) | 2026-08-24 |
| Brown Michael Jon | EVP Chief Legal Compliance Off | 14 | — | $1,0M (8) | 2026-10-19 |
| Leach Jacob Steven | President, CEO, and Director | 7 | $1,0M (1) | — | 2026-08-25 |
| Coleman Jon | EVP, Chief Commercial Officer | 4 | — | $723k (2) | 2026-06-05 |
| Augustinos Nicholas | Consejero | 6 | — | $680k (2) | 2026-09-16 |
| Sylvain Jereme M | EVP, Chief Financal Officer | 8 | — | $661k (2) | 2026-09-14 |
| Foletta Mark G | Consejero | 6 | — | $627k (3) | 2026-08-04 |
| Stern Sadie | EVP Chief People & Culture Off | 9 | — | $565k (3) | 2026-09-30 |
Se enseñan los 8 que más dinero movieron, de 17. Los demás están en el histórico completo, que se abre con el enlace de arriba. El nombre lleva a todas sus operaciones, en cualquier empresa. «Transacciones» cuenta cualquier código; el dinero, solo mercado abierto. Cargo: el de su última declaración.
Mes a mes
Por el mes en que se operó, no en el que se presentó el formulario; los meses sin operaciones van a cero. El mes con más movimiento fue ago 2026: 0 compras y 5 ventas, por $3,1M. 4 de los 15 meses no tienen ninguna.
| Mes | Compras | Importe | Ventas | Importe |
|---|---|---|---|---|
| ago 2025 | 0 | $0 | 0 | $0 |
| sept 2025 | 0 | $0 | 3 | $529k |
| oct 2025 | 0 | $0 | 0 | $0 |
| nov 2025 | 1 | $1,0M | 3 | $448k |
| dic 2025 | 0 | $0 | 0 | $0 |
| ene 2026 | 0 | $0 | 0 | $0 |
| feb 2026 | 0 | $0 | 1 | $69k |
| mar 2026 | 0 | $0 | 1 | $110k |
| abr 2026 | 0 | $0 | 1 | $107k |
| may 2026 | 0 | $0 | 3 | $2,1M |
| jun 2026 | 0 | $0 | 4 | $1,1M |
| jul 2026 | 0 | $0 | 4 | $4,3M |
| ago 2026 | 0 | $0 | 5 | $3,1M |
| sept 2026 | 0 | $0 | 5 | $1,3M |
| oct 2026 | 0 | $0 | 1 | $145k |
El último mes puede ir incompleto: el Formulario 4 se presenta hasta dos días hábiles después. La tabla no dice si el patrón es bueno o malo; dice cuándo pasó.
Ficha de análisis de DexCom, Inc. (DXCM) →
Otras empresas de Salud con operaciones de directivos
Están las 500 en el índice de la sección →
Qué directivos están comprando acciones de su propia empresa →
Cómo leer estos datos
19 de las 19 ventas de la tabla van marcadas como programadas (plan 10b5-1): se firman con meses de antelación y se ejecutan solas, así que no dicen lo que el directivo piensa hoy. La única compra en mercado abierto (código P) de DexCom es la señal rara: los directivos ya cobran en acciones, y comprar más es poner dinero propio. La última presentación es del 19 oct 2026, y el Formulario 4 llega hasta dos días hábiles después de operar.
20 de las 20 filas de la tabla llevan notas al pie del propio Formulario 4, plegadas en la columna del código y copiadas tal cual, en inglés; una fila sin nota es que el formulario no la trae.
Guía: Compras de directivos · todas las guías
Lo que hay detrás de estas operaciones
Los conceptos de esta página, explicados desde cero en la Academia. Gratis y sin cuenta.
- Qué dice y qué NO dice la hipótesis de eficienciaSi la compra de un directivo es pública y cualquiera puede leerla, ¿queda información dentro? Es la pregunta exacta que trae a esta página.
- Quién mueve realmente el mercado: los tipos de inversoresQuién hay al otro lado de cada orden, y qué sitio ocupan entre ellos los directivos de la propia empresa.
- Oferta, demanda y el precio: por qué sube y baja constantementeCómo acaba una noticia metida en el precio, y por qué la reacción a una venta declarada rara vez es la que uno esperaría.
Fuente: SEC EDGAR Formulario 4. Esto es una lista de hechos públicos, no asesoramiento financiero ni una recomendación de compra o venta.